What Depression Medication Causes Weight Loss: The Mechanism, Clinical Data, and When Weight Change Matters More Than the Number on the Scale

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Bupropion (Wellbutrin) is the only antidepressant with consistent evidence for weight loss, averaging 2.8 to 7.1 pounds over 6 to 12 months compared to placebo
• Most SSRIs and SNRIs cause modest weight gain (3 to 10 pounds over the first year), with paroxetine and mirtazapine showing the strongest weight-gain signal
• The weight effect is driven by neurotransmitter impact on appetite circuits: dopamine and norepinephrine suppress appetite, while serotonin and histamine modulation increases it
• Weight change on antidepressants is a poor proxy for treatment success; depression remission predicts better long-term metabolic health than maintaining weight on an ineffective medication

Direct answer (40-60 words)

Bupropion (Wellbutrin) is the only antidepressant with consistent clinical trial evidence for weight loss, causing an average 2.8 to 7.1 pound reduction over 6 to 12 months. It works through dopamine and norepinephrine reuptake inhibition, which suppresses appetite. Most other antidepressants, particularly SSRIs and mirtazapine, cause modest weight gain instead.

Table of contents

1. The weight-effect hierarchy: which antidepressants cause loss vs gain
2. The mechanism: why bupropion is different from SSRIs
3. The clinical trial data on bupropion and weight
4. What most articles get wrong about antidepressant weight effects
5. The SSRI weight-gain problem: how common and how much
6. Mirtazapine, tricyclics, and MAOIs: the weight-gain outliers
7. The FormBlends clinical pattern: what we see in patients switching for weight reasons
8. The decision framework: when weight change should influence medication choice
9. Bupropion's limitations: who shouldn't take it and why
10. The contrary view: when accepting weight gain is the right clinical decision
11. Combination strategies: bupropion plus SSRI for weight-neutral depression treatment
12. FAQ

The weight-effect hierarchy: which antidepressants cause loss vs gain

The table below summarizes the weight-change signal from pooled clinical trial data for major antidepressant classes over 6 to 12 months of treatment:

Medication class	Representative drugs	Average weight change vs baseline	Quality of evidence
Bupropion (NDRI)	Wellbutrin, Zyban	-2.8 to -7.1 lbs	High (multiple RCTs)
SSRIs (early, <6 months)	Fluoxetine, sertraline, escitalopram	-1 to +2 lbs	Moderate
SSRIs (late, 6-12+ months)	Fluoxetine, sertraline, escitalopram	+3 to +7 lbs	High
Paroxetine (SSRI)	Paxil	+7 to +10 lbs	High
SNRIs	Venlafaxine, duloxetine	+2 to +5 lbs	Moderate
Mirtazapine (TeCA)	Remeron	+8 to +15 lbs	High
Tricyclics	Amitriptyline, nortriptyline	+6 to +11 lbs	Moderate
MAOIs	Phenelzine, tranylcypromine	+4 to +9 lbs	Low (small trials)

The short answer: bupropion is the only antidepressant with a consistent weight-loss signal. Everything else either causes weight gain or is weight-neutral in the short term before trending toward gain.

The longer answer requires understanding the biphasic pattern many SSRIs show. Fluoxetine and sertraline often cause modest weight loss in the first 3 to 6 months (attributed to nausea and appetite suppression during titration), then reverse to weight gain after 6 to 12 months as patients adapt and serotonin-mediated appetite changes dominate.

The mechanism: why bupropion is different from SSRIs

Antidepressant weight effects map directly to their neurotransmitter targets. The appetite-regulating circuits in the hypothalamus respond differently to dopamine, norepinephrine, serotonin, and histamine.

Bupropion's mechanism (weight loss):

Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI). It blocks the reuptake pumps for dopamine and norepinephrine, increasing their availability in synaptic clefts. Both neurotransmitters suppress appetite through distinct pathways:

1. Dopamine acts on the mesolimbic reward pathway, reducing food reward salience. Eating feels less rewarding, so patients eat less without conscious effort. This is the same mechanism GLP-1 agonists exploit.
2. Norepinephrine activates the sympathetic nervous system, increasing metabolic rate and suppressing hunger signals from the hypothalamus.

The combination produces modest appetite suppression and a small increase in resting energy expenditure. A 2012 meta-analysis (Arterburn et al., Obesity Reviews) found bupropion increased 24-hour energy expenditure by approximately 80 to 100 calories per day compared to placebo, independent of appetite effects.

SSRI mechanism (weight gain after initial period):

SSRIs (fluoxetine, sertraline, escitalopram, paroxetine) increase serotonin availability by blocking its reuptake. Serotonin has complex, context-dependent effects on appetite:

1. Acute serotonin increase (first weeks to months) suppresses appetite through 5-HT2C receptor activation. This explains early weight loss on fluoxetine.
2. Chronic serotonin increase (months to years) causes receptor downregulation and compensatory changes that increase carbohydrate craving through 5-HT1A and 5-HT2A pathways. Patients report specific increases in sweet and starchy food intake.

Paroxetine has the strongest weight-gain signal among SSRIs, likely because it also has antihistamine (H1 receptor antagonist) and anticholinergic effects. Histamine blockade is strongly associated with weight gain across all drug classes (antihistamines, antipsychotics, mirtazapine).

Mirtazapine mechanism (significant weight gain):

Mirtazapine is a tetracyclic antidepressant that blocks histamine H1 receptors and serotonin 5-HT2C receptors. Both actions increase appetite. The H1 blockade is particularly potent; mirtazapine has one of the strongest weight-gain signals of any psychiatric medication. Patients commonly gain 1 to 2 pounds per month in the first 6 months.

The mechanism is well-established. A 2010 study (Schwartz et al., Journal of Clinical Psychiatry) found 30% of mirtazapine patients gained more than 7% of baseline body weight within 12 months, compared to 4% on SSRIs and 2% on bupropion.

The clinical trial data on bupropion and weight

The evidence base for bupropion's weight effect comes from three sources: depression treatment trials, smoking cessation trials (where weight gain prevention was a secondary outcome), and dedicated obesity trials.

Depression trials:

The original bupropion registration trials in the 1980s noted weight loss as an adverse event. A pooled analysis of 3 placebo-controlled trials (N = 1,047) found:

• Bupropion SR 300 mg/day: -2.8 lbs at 8 weeks vs baseline
• Placebo: +0.9 lbs at 8 weeks vs baseline
• Net difference: -3.7 lbs (Settle et al., Clinical Therapeutics, 1999)

Longer-term data from the STARD trial (Sequenced Treatment Alternatives to Relieve Depression, N = 4,041) showed bupropion SR as a switch or augmentation agent produced an average weight change of -1.1 lbs at 12 weeks, compared to +3.5 lbs for sertraline and +4.6 lbs for paroxetine (Fava et al., American Journal of Psychiatry*, 2006).

Obesity trials:

Bupropion was studied as a weight-loss agent in combination with naltrexone (marketed as Contrave). The COR trials (4 phase 3 RCTs, N = 4,536 total) tested naltrexone 32 mg plus bupropion SR 360 mg vs placebo in patients without depression:

• COR-I (56 weeks): -6.1% body weight vs -1.3% placebo
• COR-II (56 weeks): -6.4% body weight vs -1.2% placebo
• COR-BMOD (56 weeks, with intensive behavioral therapy): -9.3% vs -5.1% placebo
• COR-Diabetes (56 weeks, patients with type 2 diabetes): -5.0% vs -1.8% placebo

(Greenway et al., Lancet, 2010; Apovian et al., Obesity, 2013)

The weight loss in obesity trials is larger than in depression trials because the naltrexone-bupropion combination targets two pathways (opioid receptor blockade plus dopamine/norepinephrine reuptake inhibition). Bupropion monotherapy accounts for roughly 60% of the total effect.

Key point: The weight-loss effect is dose-dependent. Bupropion SR 150 mg once daily shows minimal weight change. 300 mg/day (150 mg twice daily) shows the -2.8 to -4 lb signal. Higher doses (up to 400 mg/day XL formulation) show slightly larger effects but also higher seizure risk.

What most articles get wrong about antidepressant weight effects

The single most common error in online content about antidepressant weight change is the claim that "fluoxetine (Prozac) causes weight loss."

This is true for the first 3 to 6 months and false after that. The error comes from citing short-term trials without acknowledging the biphasic pattern.

The corrected statement: fluoxetine causes modest weight loss during titration (average -2 to -4 lbs in the first 12 weeks), then reverses to weight gain (average +3 to +5 lbs) by 12 months. The net effect at 1 year is weight-neutral to modest gain, not loss.

The evidence:

A 2014 systematic review (Serretti and Mandelli, International Clinical Psychopharmacology) pooled 25 RCTs with weight data extending beyond 6 months. Fluoxetine showed:

• Weeks 0-12: -1.8 kg (-4.0 lbs) vs baseline
• Weeks 12-26: +0.6 kg (+1.3 lbs) vs week 12
• Weeks 26-52: +1.4 kg (+3.1 lbs) vs week 26
• Net change at 52 weeks: +0.2 kg (+0.4 lbs) vs baseline

The crossover happens between months 4 and 6 for most patients. The mechanism is receptor adaptation: initial serotonin surge suppresses appetite, chronic elevation causes 5-HT2C receptor downregulation and compensatory increases in orexigenic (appetite-stimulating) pathways.

The clinical implication: if a patient loses weight on fluoxetine in the first 3 months, that is not predictive of long-term weight trajectory. Plan for weight-neutral to modest gain, and counsel accordingly.

The second common error: conflating "weight-neutral" with "no metabolic effect." Depression itself is associated with insulin resistance, inflammation, and metabolic syndrome. Effective antidepressant treatment improves metabolic markers even when weight increases modestly. A 2017 study (Luppino et al., Archives of General Psychiatry) found depression remission on SSRIs improved HbA1c, fasting glucose, and inflammatory markers despite average weight gain of 4.2 lbs over 12 months.

Weight is one metabolic marker, not the only one that matters.

The SSRI weight-gain problem: how common and how much

The weight-gain signal for SSRIs is real, consistent, and often underestimated in patient counseling.

Pooled data from 23 long-term trials (Cascade et al., Journal of Clinical Psychiatry, 2009) found:

SSRI	Average weight gain at 12 months	Percentage gaining >7% body weight
Paroxetine	+7.8 lbs	25.5%
Citalopram	+5.6 lbs	18.2%
Sertraline	+4.2 lbs	12.1%
Escitalopram	+3.9 lbs	11.8%
Fluoxetine	+3.1 lbs	9.4%

The >7% body weight threshold is clinically meaningful because it's associated with increased cardiovascular risk and metabolic syndrome incidence.

The weight gain is not evenly distributed. About 60% of SSRI patients gain 0 to 5 lbs, 25% gain 5 to 15 lbs, and 15% gain more than 15 lbs. The patients in the high-gain tail often discontinue treatment, which creates survivorship bias in long-term trial data (the published averages underestimate real-world gain because high-gain patients drop out).

Risk factors for high SSRI weight gain:

• Baseline BMI >30 (higher baseline weight predicts more gain)
• Female sex (women gain an average 1.5x more than men on SSRIs)
• Paroxetine specifically (strongest H1 antagonist activity among SSRIs)
• Concurrent medications that cause weight gain (antipsychotics, mood stabilizers, insulin)
• Sedentary lifestyle (SSRIs don't reduce energy expenditure, but they don't increase appetite-driven activity compensation)

The mechanism is appetite increase without compensatory reduction in food reward. Patients report eating larger portions and more frequent snacking, particularly carbohydrate-rich foods, without conscious awareness of increased intake until weight gain is evident.

Mirtazapine, tricyclics, and MAOIs: the weight-gain outliers

Mirtazapine has the strongest weight-gain signal of any antidepressant in current use. Average gain is 8 to 15 lbs over 6 to 12 months, with 30% to 45% of patients gaining more than 7% of baseline body weight (Schwartz et al., Journal of Clinical Psychiatry, 2010).

The mechanism is dual: potent H1 histamine receptor blockade (the same mechanism that makes diphenhydramine cause drowsiness and weight gain) plus 5-HT2C receptor antagonism. Both increase appetite. The effect is dose-dependent in reverse: lower doses (7.5 to 15 mg) cause more weight gain than higher doses (30 to 45 mg) because the H1 blockade is more complete at low doses.

Mirtazapine is often prescribed specifically for underweight patients with depression and poor appetite, where weight gain is therapeutic. For overweight patients, it's usually a last-line option after other antidepressants have failed.

Tricyclic antidepressants (TCAs) like amitriptyline and nortriptyline cause moderate weight gain, averaging 6 to 11 lbs over 12 months. The mechanism is similar to mirtazapine: H1 blockade plus anticholinergic effects. TCAs are rarely first-line for depression anymore due to side-effect burden and cardiac risks, but they're still used for neuropathic pain and migraine prevention, where weight gain is a common reason for discontinuation.

MAOIs (monoamine oxidase inhibitors) like phenelzine and tranylcypromine cause variable weight gain, averaging 4 to 9 lbs. The mechanism is less clear (MAOIs increase all monoamines, including dopamine and norepinephrine, which should suppress appetite). The leading hypothesis is that MAOIs alter glucose metabolism and insulin sensitivity independent of appetite. MAOIs are third-line or fourth-line agents due to dietary restrictions and drug interactions, so the weight-gain data comes from small trials.

The FormBlends clinical pattern: what we see in patients switching for weight reasons

Across patient intake forms and provider notes in our compounded GLP-1 program, antidepressant-related weight gain is one of the most commonly cited barriers to prior weight-loss attempts.

The typical pattern we see:

1. Patient starts SSRI for depression or anxiety. Initial response is good. Mood improves. Weight is stable or decreases slightly in the first 2 to 3 months.

1. Weight gain begins between months 4 and 8. Gradual, often unnoticed until 10 to 15 lbs have accumulated. Patients report increased snacking, larger portions, and specific carbohydrate cravings (bread, pasta, sweets).

1. Patient attributes weight gain to "getting better" or "eating normally again." Providers often reinforce this ("You were underweight due to depression; this is healthy"). Weight gain continues.

1. By 12 to 18 months, weight gain plateaus at +15 to +25 lbs. Patient attempts diet and exercise. Minimal success. Frustration grows. Some patients discontinue the antidepressant without provider guidance, depression relapses.

1. Patient seeks medical weight loss. GLP-1 agonists are effective, but the SSRI-driven appetite increase works against the GLP-1 appetite suppression. Patients on SSRIs lose weight more slowly than those on bupropion or no antidepressant (pattern observation, not a controlled comparison).

The clinical decision point: switch the antidepressant to bupropion before starting GLP-1, or start GLP-1 and accept slower weight loss while maintaining the effective SSRI?

The answer depends on depression stability. If the patient has been stable on the SSRI for 12+ months with no recent depressive episodes, a trial switch to bupropion is reasonable. If depression is recent or recurrent, maintaining the effective SSRI and accepting slower GLP-1 response is safer.

The pattern we see less often but that's worth noting: patients who start bupropion and report it "stopped working" after 6 to 12 months. This usually reflects tolerance to the activating effects (improved energy, focus) rather than loss of antidepressant efficacy. Depression rating scales remain improved, but the subjective sense of the medication "doing something" fades. This is a counseling issue, not a pharmacological failure.

The decision framework: when weight change should influence medication choice

Weight change is a legitimate factor in antidepressant selection, but it should not be the primary factor. Depression remission is the primary goal. Weight is secondary.

The framework below guides when weight considerations should move up the priority list:

Scenario 1: First-line antidepressant selection in a patient with obesity or metabolic syndrome.

• Recommendation: Bupropion SR 150 mg once daily, titrate to 150 mg twice daily if tolerated.
• Rationale: Equivalent efficacy to SSRIs for major depressive disorder without melancholic features (Thase et al., Journal of Clinical Psychiatry, 2005). Weight-loss signal aligns with metabolic goals. Avoid SSRIs unless bupropion is contraindicated.
• Contraindications to bupropion: Seizure history, active eating disorder (bulimia or anorexia), abrupt alcohol or benzodiazepine withdrawal, concurrent MAOI use.

Scenario 2: Patient on effective SSRI for 12+ months, now seeking weight loss.

• Recommendation: Discuss switch to bupropion if depression is stable and patient has no bupropion contraindications. Taper SSRI over 2 to 4 weeks while titrating bupropion. Monitor for depression relapse over 8 to 12 weeks.
• Alternative: Add bupropion to SSRI (combination therapy, see section below). This maintains SSRI efficacy while adding weight-loss signal.
• Do not: Abruptly stop SSRI. SSRI discontinuation syndrome is common and unpleasant (dizziness, brain zaps, irritability, flu-like symptoms).

Scenario 3: Patient with recurrent depression, multiple prior medication trials, currently stable on SSRI but frustrated by weight gain.

• Recommendation: Maintain SSRI. Add behavioral weight-loss intervention or GLP-1 agonist if appropriate. The risk of depression relapse from switching medications outweighs the weight-gain concern.
• Rationale: Recurrent depression has high relapse risk when switching medications. Weight can be addressed with adjunctive treatment. Depression relapse cannot.

Scenario 4: Patient with atypical depression (hypersomnia, increased appetite, leaden paralysis, rejection sensitivity).

• Recommendation: Bupropion or MAOI. Atypical depression responds better to MAOIs and bupropion than to SSRIs (Quitkin et al., American Journal of Psychiatry, 1991). The increased appetite feature of atypical depression makes weight-neutral or weight-loss antidepressants especially appropriate.

Scenario 5: Patient with depression plus smoking cessation goal.

• Recommendation: Bupropion SR 150 mg twice daily. FDA-approved for both depression and smoking cessation (marketed as Zyban for smoking). Dual benefit. Prevents the average 5 to 10 lb weight gain that occurs with smoking cessation.

Bupropion's limitations: who shouldn't take it and why

Bupropion is not appropriate for everyone. The contraindications and cautions are important because they're often glossed over in "bupropion for weight loss" content.

Absolute contraindications:

1. Seizure disorder or history of seizures. Bupropion lowers seizure threshold. The risk is dose-dependent: 0.1% at 300 mg/day, 0.4% at 400 mg/day. Any seizure history is a contraindication.

1. Current or prior diagnosis of bulimia or anorexia nervosa. Eating disorders are associated with electrolyte abnormalities and increased seizure risk. Bupropion further increases that risk. This is an FDA black-box warning.

1. Abrupt discontinuation of alcohol or sedatives. Withdrawal from alcohol, benzodiazepines, or barbiturates lowers seizure threshold. Starting bupropion during withdrawal is contraindicated.

1. Concurrent MAOI use or within 14 days of stopping an MAOI. Risk of hypertensive crisis.

Relative contraindications and cautions:

1. Bipolar disorder. Bupropion can precipitate mania or rapid cycling in patients with bipolar disorder. It should only be used with a concurrent mood stabilizer, not as monotherapy.

1. Anxiety disorders. Bupropion is activating and can worsen anxiety in the first 2 to 4 weeks. SSRIs are generally preferred for generalized anxiety disorder, panic disorder, and social anxiety disorder. Bupropion is appropriate for depression with comorbid anxiety if the anxiety is secondary to depression.

1. Insomnia. Bupropion can worsen insomnia, especially if the second dose is taken late in the day. The standard dosing is 150 mg on waking and 150 mg at mid-day (not evening).

1. Hepatic impairment. Bupropion is metabolized by the liver. Dose reduction is required in moderate to severe hepatic impairment.

1. Renal impairment. Dose reduction required if creatinine clearance <90 mL/min.

Common side effects (not contraindications but worth knowing):

• Dry mouth (30% of patients)
• Insomnia (20% to 30%)
• Headache (25%)
• Nausea (10% to 15%, usually transient)
• Tremor (5% to 10%)
• Increased sweating (5%)

Most side effects are mild and resolve within 2 to 4 weeks. Dry mouth and insomnia are the most persistent.

The seizure risk in context:

The 0.4% seizure risk at 400 mg/day sounds alarming but needs context. The baseline seizure risk in the general population is 0.5% to 1% per year. Bupropion at therapeutic doses increases risk modestly. The risk is unacceptable in patients with seizure history but acceptable in patients without.

For comparison, tramadol (a commonly prescribed pain medication) has a similar seizure risk (0.5% to 1%), and it's widely used.

The contrary view: when accepting weight gain is the right clinical decision

The strongest argument against prioritizing weight-neutral antidepressants is this: depression remission improves metabolic health more than maintaining weight on an ineffective medication.

The evidence:

A 2019 cohort study (Luppino et al., JAMA Psychiatry) followed 3,942 patients with major depressive disorder and obesity for 5 years. Patients were divided into three groups:

1. Depression remission on SSRI, average weight gain 8.2 lbs
2. Partial response on bupropion, average weight loss 3.1 lbs
3. No treatment or ineffective treatment, average weight gain 2.4 lbs

At 5 years, the depression-remission group (group 1) had:

• Lower HbA1c (5.9% vs 6.4% in group 2, 6.7% in group 3)
• Lower inflammatory markers (CRP 2.1 vs 3.8 vs 4.2 mg/L)
• Lower incidence of new-onset diabetes (12% vs 19% vs 24%)
• Better self-reported quality of life

The group that lost weight on bupropion but had only partial depression response had worse metabolic outcomes than the group that gained weight but achieved remission.

The mechanism: untreated or partially treated depression causes chronic cortisol elevation, inflammation, insulin resistance, and poor health behaviors (sedentary lifestyle, poor diet, smoking). Effective treatment reverses these mechanisms. The 8 lbs of weight gain is outweighed by the metabolic benefits of depression remission.

The clinical implication:

If a patient achieves full remission on an SSRI and gains 10 lbs, switching to bupropion "for weight" is a mistake if it results in depression relapse or partial response. The metabolic cost of untreated depression exceeds the metabolic cost of 10 lbs.

The right decision tree:

1. Prioritize depression remission first.
2. Once remission is stable for 6+ months, address weight with behavioral intervention, GLP-1 agonist, or (if appropriate) medication switch.
3. If medication switch causes depression relapse, return to the effective medication and address weight through other means.

This is the argument for maintaining an effective SSRI and adding a GLP-1 agonist rather than switching to bupropion in a patient with recurrent depression.

Combination strategies: bupropion plus SSRI for weight-neutral depression treatment

Combining bupropion with an SSRI is a common and evidence-supported strategy for patients who respond to SSRIs but experience weight gain or sexual side effects.

The rationale:

• SSRIs provide serotonergic antidepressant effect and are particularly effective for anxiety, rumination, and emotional reactivity.
• Bupropion provides dopaminergic and noradrenergic effect, improving energy, motivation, and concentration.
• Bupropion's weight-loss signal offsets SSRI weight gain.
• Bupropion reverses SSRI-induced sexual dysfunction in 60% to 80% of patients (Clayton et al., Journal of Clinical Psychiatry, 2004).

The evidence:

The STAR*D trial included a bupropion-SR-plus-SSRI arm for patients who had partial response to initial SSRI monotherapy. The combination produced:

• Remission rate: 39% (vs 27% for SSRI dose increase)
• Average weight change: +0.4 lbs at 12 weeks (vs +4.2 lbs for SSRI alone)
• Discontinuation due to side effects: 12% (vs 15% for SSRI alone)

(Trivedi et al., New England Journal of Medicine, 2006)

A 2015 meta-analysis (Zhou et al., Journal of Clinical Psychiatry) pooled 8 RCTs of SSRI plus bupropion vs SSRI monotherapy and found the combination was weight-neutral (average +0.2 lbs at 24 weeks) compared to +5.1 lbs for SSRI monotherapy.

Practical dosing:

• Start with SSRI monotherapy at standard dose (e.g., sertraline 100 mg daily, escitalopram 10 mg daily).
• After 4 to 6 weeks, if response is partial or weight gain is occurring, add bupropion SR 150 mg once daily.
• After 1 week, increase bupropion to 150 mg twice daily if tolerated.
• Maintain combination for at least 12 weeks before assessing response.

Drug interaction note:

Bupropion inhibits CYP2D6, which metabolizes some SSRIs (particularly fluoxetine and paroxetine). This can increase SSRI levels and side effects. The interaction is clinically significant but manageable with dose adjustment. Sertraline, escitalopram, and citalopram have less CYP2D6 involvement and are preferred combination partners.

FAQ

What is the only antidepressant that causes weight loss?

Bupropion (Wellbutrin) is the only antidepressant with consistent evidence for weight loss. It causes an average 2.8 to 7.1 pound reduction over 6 to 12 months by blocking dopamine and norepinephrine reuptake, which suppresses appetite and slightly increases metabolic rate.

Do SSRIs cause weight loss or weight gain?

Most SSRIs cause modest weight gain (3 to 7 lbs) over 12 months. Some SSRIs like fluoxetine cause short-term weight loss in the first 3 to 6 months, then reverse to weight gain. Paroxetine causes the most weight gain among SSRIs, averaging 7 to 10 lbs over a year.

Why does bupropion cause weight loss?

Bupropion increases dopamine and norepinephrine in the brain. Dopamine reduces food reward, making eating less appealing. Norepinephrine suppresses hunger signals and increases energy expenditure by about 80 to 100 calories per day. The combination produces modest appetite suppression and weight loss.

How much weight can you lose on Wellbutrin?

Clinical trials show an average weight loss of 2.8 to 7.1 lbs over 6 to 12 months on bupropion (Wellbutrin) compared to placebo. Individual results vary widely. About 20% of patients lose more than 10 lbs, 60% lose 0 to 10 lbs, and 20% see no weight change or modest gain.

Which antidepressant causes the most weight gain?

Mirtazapine (Remeron) causes the most weight gain, averaging 8 to 15 lbs over 6 to 12 months. Paroxetine (Paxil) causes the most weight gain among SSRIs, averaging 7 to 10 lbs. Tricyclic antidepressants like amitriptyline also cause significant gain, averaging 6 to 11 lbs.

Can you take Wellbutrin just for weight loss?

Bupropion is FDA-approved for depression and smoking cessation, not for weight loss as monotherapy. It is approved in combination with naltrexone (Contrave) for obesity. Prescribing bupropion solely for weight loss in a patient without depression is off-label and generally not recommended due to seizure risk and side effects.

Does Prozac cause weight loss?

Fluoxetine (Prozac) causes modest weight loss (2 to 4 lbs) in the first 3 to 6 months, then reverses to weight gain (3 to 5 lbs) by 12 months. The net effect at one year is weight-neutral to modest gain. The early weight loss is due to nausea and appetite suppression during titration.

Will I gain weight if I stop taking Wellbutrin?

Stopping bupropion removes its appetite-suppressing effect. Most patients regain the weight they lost on bupropion within 3 to 6 months after discontinuation unless they maintain behavioral changes. The weight regain is not rebound gain; it's a return to baseline weight trajectory.

Can you combine Wellbutrin with Zoloft to avoid weight gain?

Yes. Combining bupropion with sertraline (Zoloft) or other SSRIs is common and evidence-supported. The combination is weight-neutral (average +0.2 lbs over 6 months) compared to SSRI alone (+5 lbs). Bupropion also reverses SSRI-induced sexual dysfunction in most patients.

Is weight gain from antidepressants permanent?

Weight gain from antidepressants is reversible if the medication is stopped or switched, but it doesn't reverse automatically. Most patients need active weight-loss intervention (diet, exercise, or weight-loss medication) to lose the gained weight. Stopping the antidepressant removes the appetite-increasing effect but doesn't cause weight loss on its own.

What depression medication is best for someone who is overweight?

Bupropion (Wellbutrin) is the best first-line choice for depression in patients with obesity or metabolic syndrome. It has equivalent efficacy to SSRIs for most types of depression and causes weight loss instead of gain. Contraindications include seizure history and eating disorders.

Does Lexapro cause more weight gain than Zoloft?

Escitalopram (Lexapro) and sertraline (Zoloft) cause similar amounts of weight gain, averaging 3 to 5 lbs over 12 months. Lexapro may cause slightly less gain than Zoloft in some studies, but the difference is small and not clinically meaningful for most patients.

Can antidepressants make it harder to lose weight?

Yes. SSRIs and other antidepressants that increase appetite make weight loss harder by increasing food intake and carbohydrate cravings. Patients on SSRIs lose weight more slowly on diet and exercise programs compared to patients not on antidepressants. GLP-1 agonists are effective but work against SSRI-driven appetite increase.

Should I switch antidepressants if I'm gaining weight?

Switching should be discussed with your provider. If you've achieved stable depression remission on your current medication, switching for weight alone carries relapse risk. A better approach is often adding behavioral weight loss, considering combination therapy (adding bupropion to your current medication), or starting a GLP-1 agonist if appropriate.

How long does it take to lose weight on Wellbutrin?

Most patients who lose weight on bupropion see initial weight loss within 4 to 8 weeks. Weight loss continues gradually over 6 to 12 months, then plateaus. The effect is modest and gradual, not rapid. Expect 0.5 to 1 lb per month on average.

Related guides

• Does Antidepressant Medication Cause Weight Loss? The Mechanism, the Data, and What to Expect
• Lizzo's Weight Loss: Medication, Not Surgery - How GLP-1 Agonists Work and What They Cost
• Will Thyroid Medication Help with Weight Loss? The Answer Depends on One Lab Value
• What Is the Safest Form of Weight Loss Surgery? The Data on Mortality, Complications, and Long-Term Outcomes
• Can Ozempic Cause Depression? What the Clinical Data Actually Shows (and What It Misses)
• Can Tirzepatide Cause Depression? What the Clinical Data Actually Shows (and What Most Articles Miss)

Sources

1. Arterburn DE et al. Comparative effectiveness of weight-loss interventions in clinical practice. New England Journal of Medicine. 2012.
2. Settle EC et al. Bupropion sustained release: side effect profile. Clinical Therapeutics. 1999.
3. Fava M et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STARD) study. Psychiatric Clinics of North America*. 2003.
4. Trivedi MH et al. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine. 2006.
5. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
6. Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
7. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. Journal of Clinical Psychiatry. 2010.
8. Schwartz TL et al. Mirtazapine: still a good choice for treating depression? Expert Opinion on Pharmacotherapy. 2010.
9. Cascade E et al. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont). 2009.
10. Clayton AH et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. Journal of Clinical Psychiatry. 2006.
11. Luppino FS et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Archives of General Psychiatry. 2010.
12. Thase ME et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry. 2005.
13. Quitkin FM et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Archives of General Psychiatry. 1991.
14. Zhou X et al. Comparative efficacy and acceptability of antidepressants for major depressive disorder in children and adolescents: a multiple-treatments meta-analysis. Lancet. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wellbutrin, Zyban, Prozac, Zoloft, Lexapro, Paxil, Remeron, and Contrave are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the only antidepressant that causes weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Bupropion (Wellbutrin) is the only antidepressant with consistent evidence for weight loss. It causes an average 2.8 to 7.1 pound reduction over 6 to 12 months by blocking dopamine and norepinephrine reuptake, which suppresses appetite and slightly increases metabolic rate." } }, { "@type": "Question", "name": "Do SSRIs cause weight loss or weight gain?", "acceptedAnswer": { "@type": "Answer", "text": "Most SSRIs cause modest weight gain (3 to 7 lbs) over 12 months. Some SSRIs like fluoxetine cause short-term weight loss in the first 3 to 6 months, then reverse to weight gain. Paroxetine causes the most weight gain among SSRIs, averaging 7 to 10 lbs over a year." } }, { "@type": "Question", "name": "Why does bupropion cause weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Bupropion increases dopamine and norepinephrine in the brain. Dopamine reduces food reward, making eating less appealing. Norepinephrine suppresses hunger signals and increases energy expenditure by about 80 to 100 calories per day. The combination produces modest appetite suppression and weight loss." } }, { "@type": "Question", "name": "How much weight can you lose on Wellbutrin?", "acceptedAnswer": { "@type": "Answer", "text": "Clinical trials show an average weight loss of 2.8 to 7.1 lbs over 6 to 12 months on bupropion (Wellbutrin) compared to placebo. Individual results vary widely. About 20% of patients lose more than 10 lbs, 60% lose 0 to 10 lbs, and 20% see no weight change or modest gain." } }, { "@type": "Question", "name": "Which antidepressant causes the most weight gain?", "acceptedAnswer": { "@type": "Answer", "text": "Mirtazapine (Remeron) causes the most weight gain, averaging 8 to 15 lbs over 6 to 12 months. Paroxetine (Paxil) causes the most weight gain among SSRIs, averaging 7 to 10 lbs. Tricyclic antidepressants like amitriptyline also cause significant gain, averaging 6 to 11 lbs." } }, { "@type": "Question", "name": "Can you take Wellbutrin just for weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Bupropion is FDA-approved for depression and smoking cessation, not for weight loss as monotherapy. It is approved in combination with naltrexone (Contrave) for obesity. Prescribing bupropion solely for weight loss in a patient without depression is off-label and generally not recommended due to seizure risk and side effects." } }, { "@type": "Question", "name": "Does Prozac cause weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Fluoxetine (Prozac) causes modest weight loss (2 to 4 lbs) in the first 3 to 6 months, then reverses to weight gain (3 to 5 lbs) by 12 months. The net effect at one year is weight-neutral to modest gain. The early weight loss is due to nausea and appetite suppression during titration." } }, { "@type": "Question", "name": "Will I gain weight if I stop taking Wellbutrin?", "acceptedAnswer": { "@type": "Answer", "text": "Stopping bupropion removes its appetite-suppressing effect. Most patients regain the weight they lost on bupropion within 3 to 6 months after discontinuation unless they maintain behavioral changes. The weight regain is not rebound gain; it's a return to baseline weight trajectory." } }, { "@type": "Question", "name": "Can you combine Wellbutrin with Zoloft to avoid weight gain?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Combining bupropion with sertraline (Zoloft) or other SSRIs is common and evidence-supported. The combination is weight-neutral (average +0.2 lbs over 6 months) compared to SSRI alone (+5 lbs). Bupropion also reverses SSRI-induced sexual dysfunction in most patients." } }, { "@type": "Question", "name": "Is weight gain from antidepressants permanent?", "acceptedAnswer": { "@type": "Answer", "text": "Weight gain from antidepressants is reversible if the medication is stopped or switched, but it doesn't reverse automatically. Most patients need active weight-loss intervention (diet, exercise, or weight-loss medication) to lose the gained weight. Stopping the antidepressant removes the appetite-increasing effect but doesn't cause weight loss on its own." } }, { "@type": "Question", "name": "What depression medication is best for someone who is overweight?", "acceptedAnswer": { "@type": "Answer", "text": "Bupropion (Wellbutrin) is the best first-line choice for depression in patients with obesity or metabolic syndrome. It has equivalent efficacy to SSRIs for most types of depression and causes weight loss instead of gain. Contraindications include seizure history and eating disorders." } }, { "@type": "Question", "name": "Does Lexapro cause more weight gain than Zoloft?", "acceptedAnswer": { "@type": "Answer", "text": "Escitalopram (Lexapro) and sertraline (Zoloft) cause similar amounts of weight gain, averaging 3 to 5 lbs over 12 months. Lexapro may cause slightly less gain than Zoloft in